Jerzy Świerkot

List of Publications by Year
in descending order

44 papers	792 citations	516710 16 h-index	552781 26 g-index
45 all docs	45 docs citations	45 times ranked	1240 citing authors

#	Article	IF	Citations
1	IL-17A, IL-17F and IL-23R Gene Polymorphisms in Polish Patients with Rheumatoid Arthritis. Archivum Immunologiae Et Therapiae Experimentalis, 2015, 63, 215-221.	2.3	63
2	Significance of Polymorphism and Expression of miR-146a and NFƙB1 Genetic Variants in Patients with Rheumatoid Arthritis. Archivum Immunologiae Et Therapiae Experimentalis, 2016, 64, 131-136.	2.3	63
3	Application of 1 H NMR-based serum metabolomic studies for monitoring female patients with rheumatoid arthritis. Journal of Pharmaceutical and Biomedical Analysis, 2016, 117, 544-550.	2.8	50
4	Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study. RMD Open, 2022, 8, e002012.	3.8	50
5	Analysis of associations between polymorphisms within genes coding for tumour necrosis factor (TNF)-alpha and TNF receptors and responsiveness to TNF-alpha blockers in patients with rheumatoid arthritis. Joint Bone Spine, 2015, 82, 94-99.	1.6	42
6	The role of diet in rheumatoid arthritis. Reumatologia, 2018, 56, 259-267.	1.1	42
7	Changes in MiRNA-5196 Expression as a Potential Biomarker of Anti-TNF-α Therapy in Rheumatoid Arthritis and Ankylosing Spondylitis Patients. Archivum Immunologiae Et Therapiae Experimentalis, 2018, 66, 389-397.	2.3	39
8	Assessment of the Effect of Methotrexate Therapy on Bone Metabolism in Patients with Rheumatoid Arthritis. Archivum Immunologiae Et Therapiae Experimentalis, 2015, 63, 397-404.	2.3	36
9	Biosimilar switching â€" current state of knowledge. Reumatologia, 2018, 56, 234-242.	1.1	33
10	The Activity of JAK/STAT and NF-κB in Patients with Rheumatoid Arthritis. Advances in Clinical and Experimental Medicine, 2016, 25, 709-717.	1.4	31
11	Prevalence and clinical characteristics of rheumatoid arthritis in Poland: a nationwide study. Archives of Medical Science, 2019, 15, 134-140.	0.9	30
12	Polymorphisms within Genes Involved in Regulation of the NF-κB Pathway in Patients with Rheumatoid Arthritis. International Journal of Molecular Sciences, 2017, 18, 1432.	4.1	29
13	Comorbidity burden and clinical characteristics of patients with difficult-to-control rheumatoid arthritis. Clinical Rheumatology, 2019, 38, 2473-2481.	2.2	26
14	The role of micro<scp>RNA</scp>â€‑5196 in the pathogenesis of systemic sclerosis. European Journal of Clinical Investigation, 2017, 47, 555-564.	3.4	25
15	Periodontal disease and influence of periodontal treatment on disease activity in patients with rheumatoid arthritis and spondyloarthritis. Rheumatology International, 2020, 40, 455-463.	3.0	24
16	Influence of NKG2D Genetic Variants on Response to Anti-TNF Agents in Patients with Rheumatoid Arthritis. Genes, 2018, 9, 64.	2.4	20
17	Replication study of polymorphisms associated with response to methotrexate in patients with rheumatoid arthritis. Scientific Reports, 2018, 8, 7342.	3.3	18
18	IL-33 Gene Polymorphisms as Potential Biomarkers of Disease Susceptibility and Response to TNF Inhibitors in Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Patients. Frontiers in Immunology, 2021, 12, 631603.	4.8	18

#	Article	IF	Citations
19	Cytokine profiles in axial spondyloarthritis. Reumatologia, 2015, 53, 9-13.	1.1	15
20	Evaluation of a clinical pharmacogenetics model to predict methotrexate response in patients with rheumatoid arthritis. Pharmacogenomics Journal, 2018, 18, 539-545.	2.0	14
21	Significance of association of HLA-C and HLA-E with psoriatic arthritis. Human Immunology, 2014, 75, 1188-1191.	2.4	13
22	Influence of CD94 and NKG2A variants on susceptibility to rheumatoid arthritis and efficacy of anti-TNF treatment. Joint Bone Spine, 2016, 83, 75-79.	1.6	10
23	Primary Immunodeficiencies: Diseases of Children and Adults â€“ A Review. Advances in Experimental Medicine and Biology, 2020, 1289, 37-54.	1.6	10
24	Association of MICA-129Met/Val polymorphism with clinical outcome of anti-TNF therapy and MICA serum levels in patients with rheumatoid arthritis. Pharmacogenomics Journal, 2020, 20, 760-769.	2.0	10
25	Complete (Humoral and Cellular) Response to Vaccination against COVID-19 in a Group of Healthcare Workers-Assessment of Factors Affecting Immunogenicity. Vaccines, 2022, 10, 710.	4.4	9
26	Activity of JAK/STAT and NF-ĸB in patients with axial spondyloarthritis. Postepy Higieny I Medycyny Doswiadczalnej, 2015, 69, 1291-1298.	0.1	8
27	The importance of ultrasound examination in early arthritis. Reumatologia, 2018, 56, 354-361.	1.1	7
28	Shared epitope and polymorphism of MICA and NKG2D encoding genes in Greek and Polish patients with rheumatoid arthritis. Central-European Journal of Immunology, 2021, 46, 92-98.	1.2	7
29	Polymorphisms within the RANK and RANKL Encoding Genes in Patients with Rheumatoid Arthritis: Association with Disease Progression and Effectiveness of the Biological Treatment. Archivum Immunologiae Et Therapiae Experimentalis, 2020, 68, 24.	2.3	6
30	Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: a subgroup analysis of a phase III randomized controlled trial in Central and Eastern European patients. Drugs in Context, 2020, 9, 1-15.	2.2	6
31	Validation of GWAS-Identified Variants for Anti-TNF Drug Response in Rheumatoid Arthritis: A Meta-Analysis of Two Large Cohorts. Frontiers in Immunology, 2021, 12, 672255.	4.8	6
32	Methotrexate treatment for rheumatoid arthritis in Poland: Retrospective analysis of patients in routine clinical practice. Reumatologia, 2018, 56, 3-9.	1.1	5
33	Polymorphisms within Genes Coding for IL-17A and F and Their Receptor as Clinical Hallmarks in Ankylosing Spondylitis. Mediators of Inflammation, 2021, 2021, 1-9.	3.0	5
34	Usefulness of noninvasive diagnostic procedures for assessment of methotrexate hepatotoxicity in patients with rheumatoid arthritis. Rheumatology International, 2022, 42, 631-638.	3.0	5
35	Autoantibody and metalloproteinase activity in early arthritis. Clinical Rheumatology, 2019, 38, 827-834.	2.2	4
36	Exploring the Extracellular Vesicle MicroRNA Expression Repertoire in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis Treated with TNF Inhibitors. Disease Markers, 2021, 2021, 1-15.	1.3	4

#	ARTICLE	IF	CITATIONS
37	Relationship Between Interleukin-6 −174G/C Genetic Variant and Efficacy of Methotrexate Treatment in Psoriatic Arthritis Patients. Pharmacogenomics and Personalized Medicine, 2021, Volume 14, 157-166.	0.7	3
38	Disease Differentiation and Monitoring of Anti-TNF Treatment in Rheumatoid Arthritis and Spondyloarthropathies. International Journal of Molecular Sciences, 2021, 22, 7389.	4.1	3
39	Searching for New Genetic Biomarkers of Axial Spondyloarthritis. Journal of Clinical Medicine, 2022, 11, 2912.	2.4	2
40	The assessment of the risk of COVID-19 infection and its course in the medical staff of a COVID-only and a non-COVID hospital. Advances in Clinical and Experimental Medicine, 2022, 31, 0-0.	1.4	1
41	Results from Polish Spondyloarthritis Initiative registry (PolSPI) â€" methodology and data from â€" the first year of observation. Reumatologia, 2017, 2, 59-64.	1.1	0
42	Addendum: Iwaszko et al., Influence of NKG2D Genetic Variants on Response to Anti-TNF Agents in Patients with Rheumatoid Arthritis. Genes 2018, 9, 64. Genes, 2018, 9, 94.	2.4	0
43	AB0411…TNF ALPHA INHIBITORS INFLUENCE THE CARDIOVASCULAR RISK IN RHEUMATOID ARTHRITIS PATIENTS. , 2019, , .		0
44	Ormond's disease accompanied by ankylosing spondylitis â€" a case report. Pomeranian Journal of Life Sciences, 2020, 66, 16-20.	0.1	0